Concepedia

Antiviral Duration Optimization

Antiviral Duration Optimization is a systematic framework in antiviral stewardship that determines the shortest effective treatment duration for antiviral therapies to maximize clinical outcomes while minimizing resistance development and adverse effects.

32

Publications

2.4K

Citations

297

Authors

147

Institutions

Publications per year

2017–2026

15

Parents

Publications

32

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

, , +15

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Charles B. Hicks, Pedro Cahn, David A. Cooper et al. · The Lancet · 2006 · 323 citations

, , +15

Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09

Janice K. Louie, Samuel Yang, M Yessenia Acosta et al. · Clinical Infectious Diseases · 2012 · 245 citations · Full text

, , +14

Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response

Ashish Goyal, E. Fabián Cardozo-Ojeda, Joshua T. Schiffer · Science Advances · 2020 · 199 citations · Full text

, , +16

Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice

Hui‐Ling Yen, Arnold S. Monto, Robert G. Webster et al. · The Journal of Infectious Diseases · 2005 · 173 citations

, , +16

1–5 of 32

Authors

297

  1. JW
    Janice Wahl

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    3 publications · 130 citations

    3

    h-index

  2. MR
    Michael Robertson

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    3 publications · 130 citations

    3

    h-index

  3. SL
    Susan L. Ford

    GlaxoSmithKline (United States), United States

    2 publications · 499 citations

    2

    h-index

  4. HD
    Harel Dahari

    Los Alamos National Laboratory, United States

    2 publications · 32 citations

    2

    h-index

  5. FP
    Fred Poordad

    Texas Liver Institute, United States

    2 publications · 87 citations

    2

    h-index

1–5 of 297

Institutions

147

  1. Universitat de Barcelona

    Barcelona, Spain

    3 h-index

    18 publications

    452 citations

  2. Loyola University Medical Center

    Maywood, United States

    2 h-index

    9 publications

    141 citations

  3. Hospital Clínic de Barcelona

    Barcelona, Spain

    2 h-index

    13 publications

    259 citations

  4. Deleted Institution

    2 h-index

    3 publications

    110 citations

  5. Sorbonne Université

    Paris, France

    2 h-index

    2 publications

    362 citations

  6. Merck & Co., Inc., Rahway, NJ, USA (United States)

    Rahway, United States

    2 h-index

    17 publications

    1K citations

  7. GlaxoSmithKline (United States)

    Philadelphia, United States

    2 h-index

    4 publications

    998 citations

  8. University of the Witwatersrand

    Johannesburg, South Africa

    2 h-index

    2 publications

    499 citations

1–8 of 147

Venues

  1. The Journal of Infectious Diseases

    JID · 3 publications · 201 citations

    3

    h-index

  2. Gastroenterology

    2 publications · 28 citations

    2

    h-index

  3. Journal of Hepatology

    2 publications · 77 citations

    2

    h-index

  4. The Lancet

    2 publications · 687 citations

    2

    h-index

  5. Open Forum Infectious Diseases

    OFID · 1 publications · 12 citations

    1

    h-index

1–5